

Erkut Borazanci

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/65320/publications.pdf>

Version: 2024-02-01

13
papers

652
citations

1162367

8
h-index

1372195

10
g-index

13
all docs

13
docs citations

13
times ranked

996
citing authors

#	ARTICLE	IF	CITATIONS
1	BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial. <i>Nature Medicine</i> , 2020, 26, 878-885.	15.2	297
2	Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE) <i>Tj ETQq0 0 0 rgBT2/Overlook10 Tf 50</i>	3.2	10
3	U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 4785-4794.	3.2	63
4	Pancreatic Cancer: "A Riddle Wrapped in a Mystery inside an Enigma" <i>Clinical Cancer Research</i> , 2017, 23, 1629-1637.	3.2	38
5	Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial. <i>Clinical Cancer Research</i> , 2021, 27, 5020-5027.	3.2	37
6	EpiPanGI Dx: A Cell-free DNA Methylation Fingerprint for the Early Detection of Gastrointestinal Cancers. <i>Clinical Cancer Research</i> , 2021, 27, 6135-6144.	3.2	26
7	Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 3214-3224.	3.2	10
8	An Analysis of Patients with DNA Repair Pathway Mutations Treated with a PARP Inhibitor. <i>Oncologist</i> , 2020, 25, e60-e67.	1.9	9
9	A Phase Ib Study of Single-Agent Idelalisib Followed by Idelalisib in Combination with Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma. <i>Oncologist</i> , 2020, 25, e1604-e1613.	1.9	9
10	Neo-adjuvant therapy for pancreatic cancer: hope for the future. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 579-589.	1.4	6
11	Hereditary Pancreatic Cancer. , 2017, , .		0
12	Partial splenic embolization to alleviate thrombocytopenia in stage III and IV pancreatic ductal adenocarcinoma patients. <i>Annals of Pancreatic Cancer</i> , 0, 2, 9-9.	1.2	0
13	Symptoms of Impending Gallbladder Perforation and Acute Cholecystitis in a Pancreatic Cancer Patient Masked by Celiac Plexus Block. <i>Gastroenterology & Hepatology (Bartlesville, Okla)</i> , 2015, 2, .	0.0	0